PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, announces the appointment of Dr Adam ...

The Starship robots were a common sight in parts of Cambridge. They frequently entertained locals with their antics, including queueing at traffic lights and facing off on street corners.

Lord Chris Smith, the former Culture Secretary and Master of Pembroke College, has been elected chancellor of the University of Cambridge. Smith won the chancellorship in a close battle with ...

A dog attack saw two people taken to hospital in Cambridge. The police were called to Topper Street with reports of a dog out of control at an address on the road on Tuesday (July 22).

PhoreMost has published new data validating its GlueSEEKER platform, a high-throughput technology designed to accelerate molecular glue drug discovery. The study outlines a systematic approach to ...

Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Clinical Research Associate (CRA) category. With just over two weeks till the 2025 competition closes for ...

Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina. The latest manufacturing investment will support the ongoing development of ...

Driver in fatal Cambridge cyclist crash pleads not guilty to motor vehicle homicide By Shannon Larson and Spencer Buell Globe Staff,Updated July 21, 2025, 4:11 p.m.

A 53-year-old man died in a fire at a motel in Cambridge Sunday morning. Police say the cause of the fire has been deemed accidental.

Chris Ratcliffe/Bloomberg British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state.

A Farlingaye teacher has received an award from the University of Cambridge.

Cambridge, UK, 22 July 2025: PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, announces ...